Welha Ziri, Director of AstraZeneca Dunkirk :
Why are you investing in Dunkirk?
«In order to increase our production, it made perfect sense to prioritise Dunkirk and make the necessary investments there…»
“The group has been increasing its investments in its Dunkirk site for many years. We’ve just finished one for 135 million US dollars and the group officially announced a new investment of the same type at the start of this year on the occasion of President Macron’s visit to our site. All the group’s analyses demonstrate that the aerosol device for the treatment of asthma and COPD (chronic obstructive pulmonary disease) that we produce in Dunkirk will see a huge growth, particularly in the Asian market. Our site has unique know-how and skills, in which the group has placed its full trust. Moreover, it is faultless from the point of view of quality, safety and supply to its customers. In order to increase our production, it made perfect sense to prioritise Dunkirk and make the necessary investments there rather than setting up a new site elsewhere. All the more so because the Dunkirk site is strategically placed at the heart of Europe, not far from an industrial port with significant logistics areas and major communication routes.”